Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Building on this, the company declared that Orforglipron would be manufactured in the U.S. Since April 2024, Eli Lilly has become the leader in new prescriptions and is gaining market share in the ...

But the latest data from Eli Lilly gives them an edge. "We'll be ready. We're gonna make this medicine here in the United States. We're building the largest, what we call API factory, which is ...

Eli Lilly (LLY.N), opens new tab, the $815 billion maker of blockbuster weight-loss drugs Mounjaro and Zepbound, is trading at more than double the valuation multiple of Wegovy maker Novo Nordisk ...